Hikma Pharmaceuticals PLC 2014 AR2
The report highlights Hikma Pharmaceuticals PLC's strong financial and operational performance in 2014, with revenue increasing by 9% to $1,489 million. The company expanded its global Injectables business through the acquisition of Bedford Laboratories and Ben Venue assets. In sustainability, Hikma renewed its UN Global Compact membership for the seventh consecutive year and achieved a score of 82 'B' in the Carbon Disclosure Project (CDP). The company also reduced its Scope 1 greenhouse gas emissions by approximately 10% compared to 2013, while continuing to invest in local communities and employee development.
Company: Hikma Pharmaceuticals PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2014
Type: AR2
Pages: 176
Back to company
Hikma Pharmaceuticals PLC
Annual Report
The report highlights Hikma Pharmaceuticals PLC's strong financial and operational performance in 2014, with revenue increasing by 9% to $1,489 million. The company expanded its global Injectables business through the acquisition of Bedford Laboratories and Ben Venue assets. In sustainability, Hikma renewed its UN Global Compact membership for the seventh consecutive year and achieved a score of 82 'B' in the Carbon Disclosure Project (CDP). The company also reduced its Scope 1 greenhouse gas emissions by approximately 10% compared to 2013, while continuing to invest in local communities and employee development.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2014
Reporting Period
Jan 1, 2014 - Dec 31, 2014
Fiscal Year
2014
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Women in Management
Employees